Canada Sylvie Pilon, VP and GM at Lundbeck Canada, shares the highlights of her first year leading the Canadian affiliate; the challenges associated with Canada’s complex market access environment, particularly for mental illnesses; Lundbeck’s commitment to supporting patient associations in order to reduce the stigma associated with mental health conditions; and…
Slovakia Lundbeck Slovakia Country Manager, Svatopluk Betina, reflects on the performance of one of the most innovative pharmaceutical firms in the region and the challenges companies face when introducing new products to the market Can you please provide an overview of Lundbeck’s presence in Slovakia and share with our audience the…
Pharma Lundbeck Mexico GM Oscar Parra discusses raising awareness of depression in Mexico, Lundbeck’s innovative treatments for depression and Alzheimer’s, and managing to navigate the country’s regulatory process to ultimately benefit the patient. Lifestyle related illnesses are a major problem in Mexico, with 13 million people suffering from diabetes and 71…
Pharma Giulio Volpe, Managing Director of Lundbeck’s Italian API’s production plant, discusses what is leading multinational companies to relocate their production to Italy, the value the Italian plant can offer the Lundbeck group and the future of API production in Italy. Could you start off with a brief overview of the…
R&D Lundbeck Turkey’s managing director discusses CNS and mental illness in Turkey, and their recent development of manufacturing operations in Turkey for their new product. Given this specialization in and deep knowledge of CNS, how would you assess the Turkish medical systems’ ability to handle mental illness? First of all, when…
CNS Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research. What have been some of the biggest successes in the last three to four years for this affiliate? The greatest…
CNS The head of Lundbeck in Canada talks about the stigma of mental illness that still exists in the country today, and how CNS companies like Lundbeck are working with stakeholders to help overcome this problem, so that sufferers of depression are treated as though they have a disease. Your…
investment The CEO of one of Denmark’s largest foundations talks about the merits of the foundation model, and the current strategies of both Lundbeck and ALK in the areas of diversification, internationalization of R&D, and what it means to be a Danish company. The end of the blockbuster era has put…
Array Ulf Wiinberg has been CEO of Lundbeck since June 2008. He was previously with Wyeth for 27 years. Ulf Wiinberg is a board member of EFPIA in Europe and of PhRMA in the United States and serves on the Industrial Policy Committee under the Confederation of Danish Industry (Dansk Industris…
Lundbeck Philippines You have been involved with Lundbeck since the beginning of its operations in the Philippines. How has the company evolved since you joined seven years ago to be where it stands now? I was contacted by the Lundbeck Regional Vice President in late 2002 and asked to come for an…
Lundbeck China Since this interview, Michael Ryde has left Lundbeck China and is now working as Commercial Counsellor, Teamleader Health, at the Danish Embassy in Beijing. Oscar Parra currently holds the position of General Manager for Lundbeck China. Lundbeck originally sold its products in China exclusively through partners for several years. What…
Lundbeck Mexico You came back to Mexico last July- what in your view have been the biggest developments in the Mexican pharmaceutical market since you were last here 11 years ago? The last time I lived in Mexico was in 2002 when the pharmaceutical industry was growing strongly and most companies were…
See our Cookie Privacy Policy Here